No currently active other malignancies which require systemic treatment Any other current or previous malignancy within years except protocol allowed malignancies Patients with previous malignancies that have been treated with systemic chemotherapy with alkylator or anthracycline therapy. The latter group of patients are excluded due to an expected increase in late effects (eg. late cardiac toxicity, secondary malignancies, sterility, etc.). Subjects with any of the following solid malignancies: Have other active malignancies or diagnosed with other malignancies within the last months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia Have prior malignancies. Participants with carcinoma in situ of any origin and participants with prior malignancies who are in remission and whose likelihood of recurrence is very low, as judged by the Lilly clinical research physician, are eligible for this study. Patients who have had chemotherapy (for other malignancies) within years prior to registration. Patients with other active malignancies are ineligible for this study, other than localized malignancies Other active malignancies. Participant has a history of other malignancies within years prior to study entry, with the exception of: Malignancies other than TNBC within years prior to randomisation) Other malignancies requiring active treatment in the last months Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin Participant has a history of other malignancies prior to study entry, with the exception of: Concurrent malignancy or malignancy within years prior to starting study drug, except\r\n* Malignancies that have completed therapy and are considered by their physician to be at less than % risk of relapse, or\r\n* Malignancies not requiring treatment (e.g., RAI stage chronic lymphocytic leukemia [CLL]) Concurrent, clinically significant, active malignancies within months of study enrollment Any concurrent active malignancies, defined as malignancies requiring any therapy other than expectant observation, since adverse events resulting from these malignancies or their treatment may confound our assessment of the safety of adoptive T cell therapy for ovarian cancer Patients with a history of other malignancies, except: Patients with multiple malignancies remain eligible Patients with other active malignancies are ineligible for this study, other than localized malignancies Concurrent malignancies Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation Have other active malignancies or diagnosed with other malignancies within the last months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation Other concomitant active malignancies Subject has a history of other malignancies .prior to study entry, with the exception of: Malignancies other than disease under study within years Malignancies other than disease under study within years prior to D of C Patients with CNS malignancies (primary or metastatic) History of other active malignancies. EXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation EXCLUSION FOR TREATMENT: Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation Any other current or previous malignancy within years except protocol allowed malignancies History of prior or concomitant malignancies within years of study start Other malignancy within years except for noninvasive malignancies Patients with other malignancies or brain metastasis are not eligible; however, given the frequent coexistence of MCC with other malignancies, the following exceptions are allowed: Patients with history of previously treated malignancies who do not have any evidence of disease for the last three years are allowed Other active malignancies Other malignancies requiring active therapy or known to be associated with altered immune response Previous malignancies Concomitant malignancies or previous malignancies with less than years disease-free interval at the time of enrollment Patients with active (uncontrolled, metastatic) second malignancies are excluded. Relapsed disease or development of other malignancies Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation, with the exception of squamous and basal cell carcinoma of skin Most concurrent second malignancies Concurrent, clinically significant, active malignancies within two years of study enrollment. History of any other active malignancies Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation History of prior or concomitant malignancies within years of study start History of other malignancies, except: History of other malignancies, except Other active malignancies Diagnosed or treated for another malignancy within years of enrollment, with the exception of in situ malignancies Subjects may not have other active malignancies other than indolent malignancies not requiring active therapy which the investigator determines are unlikely to interfere with treatment and safety analysis Other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than years. Other concurrent malignancies except skin cancer All gastrointestinal malignancies where the patient received oxaliplatin for cancer treatment or breast malignancies where patients have received docetaxel or paclitaxel for cancer treatment Patients with a new suspected or confirmed gynecologic malignancies Prior malignancies. Patient with salivary gland malignancies Patient has a history of other malignancies within the last years